Biography / Cv

  • Home
  • Biography / Cv
Speaker Name

Filippo PIETRANTONIO

Personal Details

Name and Last name Filippo Pietrantonio, MD
Place and Date of Birth Parma, 07/30/1981
Work Address: Via Venezian, 1 -20133 Milan - Italy
E-mail: filippo.pietrantonio@istitutotumori.mi.it
Mobile: +39 346/6217748

01/02/2024 – present: Director of Gastrointestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori of Milan

Present Scientific Committees and Boards:
27/01/2026 – 06/12/2026Member of the Scientific Committee for GI Tumors for ESMO Asia Congress 2026
28/01/2026 – presentMember of ESMO project “ESMO Guidance for Reporting Oncology Real-World Evidence in Abstracts (GROW.A)” e “ESMO –GROW Version 2.0”
2026Member of the Scientific Committee of the ESMO 2026 Annual meeting Upper GI Track
01/01/2026 – 31/12/2029Member of the Scientific Technical Committee (CTS) of AIRC Foundation on the Cancer research ETS
17/10/2025 – 28/10/2025Track Chair the ESMO 2025 Annual Meeting - Upper Gastrointestinal tumors
13/06/2025 – 12/06/2028Section Editor Gastrointestinal Cancer, Editorial Board of “the Oncologist” Journal
22/05/2025 – 21/05/2027Editorial Lead for Gastrointestinal tumors, Editorial Team of “Annals of Oncology” Journalas
01/03/2025 – 28/02/2028Member of the Annual Meeting Scientific Program Committee for ASCO -Lower GI Track (Colorectal and Anal cancers)
01/02/2025 – presentMember of the ESMO IVDR (In Vitro Siagnostic Regulation) Committee to mitigate the impact of IVDR implementation on cancer research in Europe
01/10/2024 – 30/09/2025Mentor for the ESMO Young Oncologist Committee (YOC) for ESMO Virtual Mentorship Porgram 2024- 2025
01/06/2024 - presentMember of the AIOM-SIF Working Group for updating the Recommendations for the pharmacogenetic analysis relative to the DPD and to fluoropirimide
01/02/2024 – presentUpdating “Guidelines syndromes for hereditary disposition of tumors” – Teamwork for AIOM
2024Member of the Scientific Committee of the ESMO 2024 Annual meeting Upper GI Track
10/01/2023 - presentNational Guidelines Coordinator in AIOM for Esophageal Tumors
31/10/2021 - 30/11/2025Member of the AIOM Directive National Council (Italian Medical Oncology Association)
01/01/2020 - presentScientific Secretary and Member of the Executive Committee of G.O.N.O. Foundation (Oncological Group from North West)
01/01/2019 - presentTask-Force Member for "Upper Gastrointestinal Cancer" and "Colorectal Cancer" European Organisation for Research and Treatment of Cancer (EORTC) - Principal Investigator at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
01/01/2016 - presentMember of Working Group "Colorectal Cancer" ACC (Alliance against Cancer)
01/01/2019 – 01/01/2020Member of Boards of Directors of G.O.N.O. Foundation (Oncological Group from North West)
Member of Associations
  • 01/04/2021 - present: ASCO (American Society of Clinical Oncology)
  • 01/01/2012 - present: ESMO (European Society for Medical Oncology)
  • 01/01/2012 - present: AIOM (Italian Medical Oncology Association)
    • Reviewer of Scientific Journals

    01/01/2012 - present: Annals of Oncology, Cancer, Cancer Cell, JAMA, British Journal of Cancer, Nature Reviews in Clinical Oncology, European Journal of Cancer, British Journal of Cancer, Cancer Research, Clinical Cancer Research, The Lancet, The Lancet Oncology, Journal of Clinical Oncology, Annals of Surgery, JCO Precision Oncology, Journal of ImmunoTherapy of Cancer, Gastric Cancer, Nature Communications, Nature Medicine, NEJM (New England Journal of Medicine), International Journal of Cancer, Clinical Colorectal Cancer, The Oncologist

    Mentorship (Young doctors attending clinical Unit visits):
    • 2024: Alexej Ballhausen - Charité – Universitätsmedizin Berlin; Silvio Ken Garattini - ASUFC-Azienda Sanitaria Universitaria del Friuli Centrale, Udine, Italy
    • 2025: Olena Bakhmatska - National Cancer Institute in Kyiv, Ukraine; Mustafa Gouldal - Alaadd Keykubat University in Antalya, Turkey; Laura Sanchez Gomez – of Barcellona, Spain; Ahmed lhadj –University of Science and Technology Mohamed Boudiaf, Algeria
    • 2026: Özlem Açıker kutlu – İzmir City Hospital, İzmir, Turkey; Laura Santa Cruz Ramiz - Hospital General Universitario, Valencia, Spain; Carmen Pertusa Gomez, General Universitario, Valencia, Spain

    Doctors attending last year’s training fellowship from Universities other than Milan

    • 2024: Carolina Liguori – University Politecnica delle Marche, Italy; Giulia Airò – University of Parma, Italy; Marta Frapoli – University of Ferrara
    • 2025: Claudia Leli – University of Pavia, Italy
    Past Activities:
    03/2018 – 01/31/2024Staff Physician, Medical Oncology Unit 1, GastroIntestinal Oncology Unit at Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    10/31/2019 - 10/31/2021Member of the AIOM Directive National Council in Lombardy (Italian Medical Oncology Association).
    03/01/2018 - 07/01/2021Researcher – University of Milan – affiliated with the Medical Oncology department – Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    10/01/2011 - 02/28/2018Consultant in the Medical Oncology 1 Unit – Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.
    10/01/2015 - 10/01/2017Member of the "Young Working Group" AIOM Committee (Italian Medical Oncology Association).
    Academic Training
    • 05/31/2021: Full Professor - National Scientific Qualification
    • 07/09/2020: Associate Professor - National Scientific Qualification
    • 09/02/2011: Specialist in Medical Oncology (Post graduate specialization) - Università degli Studi di Milano, Italy. Summa cum laude honours: “Phase II study - adjuvant chemoradiotherapy treatment with chronomodulated capecitabine in patients with high-risk rectal cancer ".
    • 03/08/2007: Registry of Physician (Parma, Italy) N°5878
    • 02/15/2007: Medical Licency
    • 10/23/2006: Medical Degree (MD) Università di Parma Italy. Summa cum laude con tesi dal titolo: "Role of the HER-2 /NEU oncogene in the etiopathogenesis of non-small cell lung cancer in patients with chronic lymphatic leukemia"
    Research Interests

    Filippo Pietrantonio, MD, is a clinician and cancer researcher focused in gastrointestinal cancers (mainly colorectal and gastric cancer), with particular focus on the design of academic clinical trials and translational medicine. Dr. Pietrantonio’s research experiences include several phase I-II-III clinical trials agents in colorectal, gastric cancer, oesophageal cancer, biliary tract cancer and pancreatic cancer.

    Research Grants Received
    • 01/01/2026: European Research Grant within the Call EP PerMed Pharmacogenomic Strategies for personalized medicine approaches (PGxPM2025) JTC 20258 project n. 061 entitled: “Immunotherapy BioMarkers an Prediction of Anti-Checkpoint therapy success in colorectal cancer (IMPACT-CRC)” - Fondazione Regionale per la Ricerca Biomedica (FRRB) – Grant holder: Filippo Pietrantonio 500.000€
    • 12/31/2024: Fondazione Cariplo – Research Grant within the Call . “ Generate Knowledge To Reduce Inequalities” – Research Project title: “Inequality and Cancer: Investigating Access to Resources for Prevention and Treatment (ICARE) “ Grant holder F. Pietrantonio 45.000€
    • 11/26/2024: AIRC Investigator Grant 2024 – Research Grant: “ Actioning the resistance mechanisms to different antibody-drug conjugates in gastric cancer” “. Grant holder F. Pietrantonio € 1.100.000€
    • 03/25/2022: Enhancement of Institutional Research 2021 Fondazione IRCCS Istituto Nazionale dei Tumori – Research Grant " Window-of-opportunity umbrella trial as a translational platform for short- course pre-operative targeted treatments in non-metastatic resectable colorectal cancer: the UNICORN study " Grant holder F. Pietrantonio - € 814.000
    • 10/14/2020: Ministry of Health Applied Research 2019 “Change Promoting”. “Temozolomide and irinotecan regimen as liquid biopsy-guided non-cross resistant sequential adjuvant treatment of patients with MGMT methylated, microsatellite stable colorectal cancer failing to achieve seroreversion after a standard adjuvant strategy “ - Grant holder F. Pietrantonio - € 449.600
    • 01/02/2020: AIRC Investigator Grant 2019 – Research Grant: "Moving forward from single-agent trastuzumab thanks to a reverse translational approach in HER2+ advanced gastric cancer" Grant holder F. Pietrantonio € 746.000
    • 01/01/2019: Enhancement of Institutional Research 2018 Fondazione IRCCS Istituto Nazionale dei Tumori - Grant research "Exploiting Liquid Biopsy To Predict Outcomes And Progression Patterns In Ras Wild-Type (Wt) Metastatic Colorectal Cancer (Mcrc) Patients Randomized To Either 5-Fu/Lv Plus Panitumumab Or Panitumumab Alone As Maintenance Strategy Following Folfox Plus Panitumumab Induction: A Pre-Planned Translational Analysis Of The Valentino Study" Grant holder F. Pietrantonio - € 40.000
    • 04/06/2018: Università degli Studi di Milano Department of Oncology and Hemato-Oncology Research Support Plan 2018 - Line 2: – Grant research: "Molecular profiling of HER2 positive metastatic gastric cancer patients with exceptional response to trastuzumab-based therapy" - Grant holder F. Pietrantonio - € 28.000
    Honor Awards
    • 11/16/2018: Award AIOM 2018 “Lecture Marco Venturini” 2018: "ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer"
    • 01/01/2016: Award "Marzia Galli Kienle" "Met-Driven resistance to dual EGFR and BRAF blockade may be overcome by Switching from EGFR to MET inhibition in BRAF-mutated colorectal cancer"- Cancer Discovery, 2016
    • 01/01/2016: Merit of Merit - Welfare Department of Lombardy
    • 06/30/2014: Award “Young Researcher” Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
    Teaching Activity
    • 11/10/2024: Mentor for the ESMO Virtual Mentorship Programme 2024-2025
    • 2023-2024: Mentor for the AIOM Virtual Wednesday
    • 2017 - present: Tutor of Medical Students - Università degli Studi di Milano
    • 2014 - present: Thesis Co-Advisor - for medicine students - Università degli Studi di Milano
    • 2019 - 2021: Postgraduate School in Orthopaedics and Traumatology - Università degli Studi di Milano - Class Of Medical Oncology.
    • 2019 - 2021: Master of Medicine and Surgery - Università degli Studi di Milano - Class Of Medical Oncology.
    • 2019 - 2021: Master of in Medical Biotechnology and Molecular Medicine - Università degli Studi di Milano - Class Of Medical Oncology.
    • 2018 - 2021: Postgraduate School in Medical Oncology - Università degli Studi di Milano - Class Of Medical Oncology.
    • 2018 - 2021: Postgraduate School of Neurosurgery - Università degli Studi di Milano - Class Of Medical Oncology.
    Trials

    Dr. Pietrantonio designed several academic no-profit trials including:

    • -(NCT.pending) Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
    • NCT07407465 Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA study
    • An observational itAlian MonoceNtric study on molecular mechanisms of rESIstAnce to Antibody-Drug Conjugates (ADCs) in gastric or gastroesophageal
    • Assessing the correlation between pathological response to neoadjuvant chemotherapy and event-free survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma” (LONGEVITY).
    • NCT06037980 phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study
    • NCT06253650 Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre- operative chemoTherapy and radical surgerY: the TRINITY study (TRINITY)
    • NCT05845450 Window-of-opportunity umbrella trial as a translational platform for short-course pre-operative targeted treatments in non-metastatic resectable colorectal cancer (UNICORN).
    • NCT04817826: TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC. (Infinity)
    • NCT05594290: Window-of-opportunity study of chemo-immunotherapy in patients with resectable MERkel Cell carcinoma prior to sUrgeRY: the MERCURY trial (MERCURY)
    • NCT05031975: Temozolomide and Irinotecan in Patients With MGMT Silenced Colorectal Cancer After Adjuvant Chemotherapy (Eraze-TMZ)
    • NCT05136326: Preoperative Chemoradiotherapy With CApecitabine and Temozolomide in MGMT Silenced, MSS, Locally Advanced RecTal Cancer (CATARTIC)
    • NCT04689347: 5FU/LV, Irinotecan, Temozolomide and Bevacizumab for MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer (FLIRT-bev)
    • NCT03832621: NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer (Maya)
    • NCT02476045: Panitumumab-based Maintenance in Patients With RAS Wild-type, Metastatic Colorectal Cancer (Valentino)
    • NCT02934464: Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers (ARMANI phase III study) – Trial Alias: H7T-IT-O004
    • NCT02414009: Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients (CAPTEM)
    • NCT02086656: Perioperative treatment with COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) of high risk or borderline resectable colorectal cancer liver metastasis (COI-B)

    Dr. Pietrantonio served and will be serving as Steering Committee Member for trials such as:

    2026-2027Rasolute 303 - Revolution Medicine
    2026Gastric (MK1022, MK2010, MK2400, MK2870 & MK3475) programs. – MSD
    2025-2026CLARITY Gastric02 - AstraZeneca
    2024-2025JNJ-61186372 (amivantamab)- OrigAMI-2 - Janssen Research & Development
    2024AMG 193 Study 20210023 - Amgen

    Dr. Pietrantonio is also an Independent Data Monitoring Committee Member for the:

    2023-2025: A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) (ARIEL) Study - Eudract number: 2021-003330- 36 - Chief Investigator: Jenny Seligmann - Professor of University of Leeds.

    Dr. Pietrantonio is also an Independent Data Monitoring Committee Chair for the:

    2024- ongoing: ZODIAC: A randomised phase II study of Zimberelimab anti-PD1 immunOtherapy +/- Domvanalimab anti- TIGIT immunotherapy in resectable mismatch repair deficient gastric and gastro-oesophageal junctional AdenoCarcinoma - Clinical trials.gov Number: NCT06250036 - Chief Investigator: Dr. Naureen Starling - Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust.

    Dr. Pietrantonio manages several academic profit and no-profit trials:

    2025Sub- Investigator: “A Prospective non-interventional study (NIS) of trastuzumab deRuxtecan (T-DXd) for adult patients with advanced HER2-pOsitive gaStric or gastroesoPhageal junction (GEJ) adEnocarcinoma who have Received a prIor Trastuzumab-based regimen, accompanied by a disease registrY of patients treated with conventional therapies in a real-world setting in Europe (PROSPERITY)”. Promoter Daiichi Sankyo Europe GmbH
    2025Principal Investigator: “A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC HER2-POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINY-GASTRIC05)”. Promoter Daiichi Sankyo Europe GmbH
    2025Principal Investigator: “A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXD) IN SUBJECTS WITH PRETREATED ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) (IDeate-Esophageal01)”. Promoter Daiichi Sankyo Europe GmbH
    2025Principal Investigator: “Single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma”. Promoter French Federation of Digestive Oncology (FFCD)
    2025Principal Investigator: “A Phase 3, Double-blind, Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2- negative, Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive”. Promoter Astellas Pharma Global Development Inc.
    2025Principal Investigator: “A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227 alone and in combination in participants with previously treated advanced unresectable”. Promoter GlaxoSmithKline Research & Development Limited
    2025Principal Investigator: “A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion”. Promoter Bristol-Myers Squibb Company
    2025Principal Investigator: “ComPrehensive evaluation and biomarker study of OxalipLAtin-related peripheRal sensory neuropathy in patients with gastrointestinal cancers: the POLAR study”. Promoter Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    2025Principal Investigator: “RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)”. (RMC-6236). Promoter Revolution Medicines, Inc.
    2025Principal Investigator: “Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)”. Promoter Amgen Inc.
    2025Sub- Investigator: “Encorafenib+Cetuximab beyond progression in combination with Folfiri in patients with BRAF V600E mutated metastatic colorectal cancer progressing on Encorafenib + Cetuximab.”. (ECLYPSE). Promoter Fondaszione Policlinico Universitario Agostino Gemelli, IRCCS
    2024Sub- Investigator: “Gemcitabine plus nab-PAclitaxel as switch maiNTEnance versus cONtinuation of modified FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: the PANThEON phase III Trial” (REVERSE). Promoter GONO Foundation
    2024Principal Investigator: “Watch-and-wait strategy to initiate Dostarlimab-based Immunotherapy in localized deficient mismatch repair (dMMR) and/or microsatellite instability high (MSI-H) oEso-gastric junction and gastric adenocarcinoma: A two-cohort open-label GERCOR phase II study” (DEWI G-123). Promoter GERCOR
    2024Sub- Investigator: “Metronomic Neoadjuvant Capecitabine and Cyclophosphamide in huge (PCI>28) Pseudomyxoma Peritonei (PMP) Patients Candidates to Cytoreductive Surgery (CRS) and Hypertermic Intraperitoneal Chemotherapy (HIPEC)” (REVERSE). Promoter Fondazione IRCCS Istituto Nazionae dei tumori di Milano
    2024Principal Investigator: “"A Phase 1/2 Study to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Gastrointestinal Cancers"”. (MK-1022-011). Promoter Merck Sharp & Dohme Corp
    2024Principal Investigator: “A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate the Safety and Efficacy of MK-2870 Plus Paclitaxel as the Second-Line Treatment of Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma: Substudy 06D”. (MK-3475-06D). Promoter Merck Sharp & Dohme Corp.
    2024Principal Investigator: “A Phase 1/2 Open-Label, Umbrella Platform Design Study of MK-2870 With Pembrolizumab (MK-3475) and Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma): Substudy 06C”. (MK-3475-06C). Promoter Merck Sharp & Dohme Corp.
    2024Sub-Investigator: “An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer”. (JZP598-302). Promoter Jazz Pharmaceuticals
    2024Sub-Investigator: “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Global Study of Rilvegostomig in Combination With Chemotherapy as Adjuvant Treatment After Resection of Biliary Tract Cancer With Curative Intent (ARTEMIDE-Biliary01)”. (D7025C00001). Promoter AstraZeneca S.p.A
    2024Sub- Investigator: “A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)” . (TT420C2308 / FIRST- 308). Promoter TRANSTHERA BIOSCIENCE
    2024Principal Investigator: “Open-label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastroesophageal junction /gastric cancer” . (CL1-95029- 002). Promoter Institut de Recherches Internationales Servier (I.R.I.S.)
    2024Principal Investigator: “A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician’s Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)” . (MK2870-015). Promoter Merck Sharp & Dohme LLC
    2024Principal Investigator: “A Phase 1/2 Study to Evaluate the Safety and Efficacy of MK-2870 Monotherapy or in Combination With Other Anticancer Agents in Gastrointestinal Cancers” . (MK9999-02A). Promoter Merck Sharp & Dohme LLC
    2024Principal Investigator: “A Phase I/II, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors” . (NOUS-209-1). Promoter Nouscom S.r.l.
    2024Principal Investigator: “Phase III randomized study of FOLFOXIRI plus BEVACIZUMAB and ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable pMMR and Immunoscore IC-high metastatic colorectal cancer patients” . (Atezotribe 2). Promoter GONO Foundation
    2024Principal Investigator: “Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first- line treatment of patients with unresectable left sided RAS/B-RAF wild-type metastatic colorectal cancer (IMPROVE- 2 trial)”. Promoter Gruppo Oncologico dell’Italia Meridionale (GOIM)
    2024Principal Investigator: “Single arm phase II study of ctDNA-guided encorafenib plus cetuximab retreatment in patients with BRAFV600E mutated mCRC..” (BRICKET). Promoter GONO Foundation
    2024Principal Investigator: “Phase II study evaluating holmium-166 TARE followed by maintenance therapy in liver limited unresectable colorectal cancer patients after first-line chemotherapy and target agents.” (HAITI)”). Promoter GONO Foundation
    2024Sub- Investigator: “Assessing the correlation between pathological response to neoadjuvant chemotherapy and event-free survival in patients with resectable gastric or gastroesophageal junction adenocarcinoma” (LONGEVITY). Promoter GONO Foundation
    2024Sub- Investigator: “Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy In HER2-positive gastric or gastroesophageal cancer patients with persistence of miNImal residual disease in liquid biopsy after pre-operative chemoTherapy and radical surgerY: the TRINITY study” (TRINITY). Promoter GONO Foundation
    2023Principal Investigator: “An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer” . (SGNTUC-029 (MOUNTANEER)). Promoter Seagen Inc.
    2023Sub-Investigator: “Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC)”. (PANDORA) Promoter Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
    2023Sub-Investigator: “A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study)”. Promoter GONO Foundation
    2023Sub-Investigator: “An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe)”. Promoter Institut de Recherches Internationales Servier (I.R.I.S.)
    2023Principal Investigator: “A Phase 1/2 First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors”. (CA043-001) Promoter Bristol-Myers Squibb Research and Development.
    2023Principal Investigator: “Window-of-opportunity umbrella platform trial of short-course pre-operative targeted treatments in patients with molecularly selected and resectable primary colorectal cancer: the UNICORN study”. Promoter GONO Foundation.
    2023Principal Investigator: “A Randomized, Open-Label, Phase 2 Study of Botensilimab (AGEN1181) as Monotherapy and in Combination with Balstilimab (AGEN2034) or Investigator’s Choice Standard of Care (Regorafenib or Trifluridine and Tipiracil) for the Treatment of Refractory Metastatic Colorectal Cancer”. Promoter Agenus, Inc.
    2023Principal Investigator: “A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/ leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI- bev) for the treatment of patients with previously treated unresectable metastatic colorectal cancer” (NuTide:323) Promoter NuCana plc
    2023Principal Investigator: “Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.” (CAPRI-2). Promoter Gruppo Oncologico dell’Italia Meridionale (GOIM).
    2023Sub-Investigator: “A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer” (Azur). Promoter GlaxoSmithKline Research & Development Limited.
    2023Principal Investigator: “A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard- of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer” (Origami). Promoter Janssen- Cilag SpA.
    2022Principal Investigator: ”A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA)”. Promoter Zymeworks Inc.
    2022Sub-Investigator: “Window-of-opportunity study of chemo-immunotherapy in patients with resectable MERkel Cell carcinoma prior to sUrgeRY: the MERCURY trial”. Promoter Fondazione GONO
    2022Principal Investigator “A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression” (FORTITUDE-102). Promoter Amgen Inc.
    2022Principal Investigator: “CAVE-2 (Cetuximab-AVElumab) mCRC: A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type metastatic colorectal cancer patients.” (CAVE-2) Promoter Gruppo Oncologico dell’Italia Meridionale (GOIM).
    2022Principal Investigator “A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06B (MK06B). Promoter Merck Sharp & Dohme Corp.
    2022Principal Investigator “A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer naïve to PD-1/PD-L1 Treatment (KEYMAKER-U06): Substudy 06A”(MK06A). Promoter Merck Sharp & Dohme Corp.
    2022Principal Investigator: “Exploiting circulating tumour DNA to intensify the postoperative treatment of stage III and high-risk stage II resected colon cancer patients with adjuvant FOLFOXIRI and/or post-adjuvant Trifluridine/Tipiracil (ERASE-CRC) Promoter Fondazione GONO.
    2022Principal Investigator: “A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants with Later-lines of Metastatic Colorectal Cancer Brief Title: A Study of Relatlimab-nivolumab Fixed-dose Combination versus Regorafenib or TAS-102 in Participants with Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123)” Promoter Bristol-Myers Squibb Company
    2022Principal Investigator “A Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib and Panitumumab Versus Investigator’s Choice (Trifluridine and Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Cancer Subjects with KRAS p.G12C Mutation”.(219-01-72). Promoter Amgen Inc.
    2022Sub-Investigator “A phase 2/3 study of ALX148 in patients with advanced HER2-overexpressing gastric/gastroesophageal junction adenocarcinoma”. Promoter ALX-Oncology Inc. (ASPEN-06)
    2022Principal Investigator “daNIS-3: An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC)” Promoter Novartis Farma S.p.A.
    2021Co-Investigator Profit Study “A global, multicenter, randomized, placebocontrolled phase 3 trial to compare the efficacy and safety of fruquintinib plus best supportive care to placebo plus best supportive care in patients with refractory metastatic colorectal cancer (FRESCO-2)” Promoter Hutchison MediPharma Limited, Coordinating Center Ospedale Policlinico San Martino - IRCCS per l’Oncologia.
    2021Principal Investigator “A phase 1/2 study exploring the safety and activity of trifluridine/tipiracil in combination with capecitabine and bevacizumab in metastatic colorectal cancer patients” Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
    2021Principal Investigator No-profit Study “Prospective observational study investigating the role of liquid biopsy and patients-derived organoids (PDOs) as novel tools for assessing tumor biology and acquired drug resistance in patients with tumors of the gastrointestinal and bilio-pancreatic tract, neuroendocrine tumors and Merkel cell carcinomas” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2021Principal Investigator “An open-label, single-arm, phase IB/IIA trial to evaluate the safety and efficacy of the EP4 receptor antagonist CR6086 in combination with the PD-1 inhibitor balstilimab (AGEN2034), in patients with pretreated mismarch-repair-proficient and microsatellite stable metastatic colorectal cancer”. Promoter Rottapharm Biotech S.r.l., Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2021Principal Investigator “A Phase 2, Multicenter, Multi Arm, Study to Evaluate Pembrolizumab (MK-3475) or MK-1308A (Co-formulated quavonlimab (MK-1308)/pembrolizumab) in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)” Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Nazionale Tumori IRCCS - Fondazione Pascale Napoli
    2021Principal Investigator No-Profit Study “Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS mutated in LIquid BIopsy to compare in first-line therapy FOLFIRI plus CetuxiMAb or BevacizumaB (LIBImAb Study)” Promoter Azienda USL-IRCCS di Reggio Emilia, Coordinating Center Azienda USL-IRCCS di Reggio Emilia
    2021Principal Investigator “A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers” Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
    2021Principal Investigator No-Profit Study “Analysis of biomarkers predicting sensitivity to immuno checkpoint inhibitors in patients with colon cancer MSI-H or with MSI-H-like phenotype after tretment with temozolomide” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2021Principal Investigator No-Profit Study “Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2021Principal Investigator Profit Study "A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma" Promoter Merck Sharp & Dohme Corporation, Coordinating Center Policlinico Universitario Gemelli (RM)
    2021Principal Investigator Profit Study "A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK-7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015)” Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) - Meldola (FC)
    2021Principal Investigator Profit Study "A Phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2 positive locally advanced unresectable or metastatic colorectal cancer (DESTINY-CRC02)” Promoter Daichi Sankyo Inc, Coordinating Center ASST Grande Ospedale Metropolitano Niguarda – Milano
    2021Co-Investigator Profit Study "A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin- Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2)” Promoter Incyte Corporation, Coordinating Center Azienda Ospedaliera Universitaria della Università Vanvitelli di Napoli
    2021Principal Investigator Profit Study “A phase 3, multicenter, 2-arm randomized, open-label study of trastuzumab deruxtecan in subjects with HER2-positive metastatic and/or unresectable gastric or gastro-esophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after trastuzumab-containing regimen (DESTINY- GASTRIC04)” Promoter Incyte Corporation, Coordinating Center Azienda Ospedaliera Universitaria della Università Vanvitelli di Napoli
    2020Principal Investigator No-profit Study " Randomized phase II study of panitumumab rechallenge followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemorefractory metastatic colorectal cancer patients”. Promoter GONO, Coordinating Center Azienda Ospedaliera Universitaria Pisana
    2020Principal Investigator No-profit Study "Phase II Study on NIVolumab in combination with FOLFOXIRI/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer RASm/BRAFm patients" Promoter GOIRC, Coordinating Center Arcispedale S. Maria Nuova - Azienda Ospedaliera di Reggio Emilia
    2020Principal Investigator No-profit Study "Phase 1b trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2020Principal Investigator No-profit Study "TremelImumab aNd durvalumab combination For the non-operatIve management (NOM) of Microsatellite InstabiliTY (MSI)-high resectable gastric or gastroesophageal junction cancer: The multicentre, single-arm, multi-cohort, Phase II INFINITY study" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2020Principal Investigator No-profit Study "Tumor and circulating biomarkers and their correlation with outcomes after priming with temozolomide and treatment with temozolomide, nivolumab and ipilimumab at low doses in patients treated within the institutional non-profit MAYA study” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2020Principal Investigator No-profit Study "Retrospective observational study on the use of immunotherapy with anti- PD-1 antibodies in patients with MSI-H metastatic colorectal cancer" Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2020Principal Investigator No-profit Study " Observational study on the rate of AMNESIA panel positivity in the large dataset of gastric cancers collected at Foundation Medicine” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2020Principal Investigator No-profit Study "A master protocol empowering Precision Research in Colorectal Cancer (ALFAOMEGA)” Promoter IFOM - Fondazione Istituto FIRC di Oncologia Molecolare, Coordinating Center A.O. Ospedale Niguarda Ca’ Granda (MI)
    2020Co-Investigator Profit Study "A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)" Promoter Basilea Pharmaceutica International AG, Coordinating Center Istituto Europeo di Oncologia (IEO)
    2020Principal Investigator Profit Study "A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants with HER2-Overexpressing Gastric Cancer (DESTINY-Gastric03)” Promoter AstraZeneca S.p.A., Coordinating Center Istituto Nazionale Tumori IRCCS “Fondazione Pascale” (NA)
    2020Co-Investigator Profit Study “A Phase 3, randomized, double-blind clinical study of pembrolizumab (MK- 3475) plus chemotherapy versus placebo plus chemotherapy as first-line treatment in participants with HER2 negative, previously untreated, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (KEYNOTE- 859)” Promoter Merck Sharp & Dohme Corporation, Coordinating Center Istituto Oncologico Veneto (IOV) – Padova
    2020Co-Investigator Profit Study “A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK- 3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975)” Promoter Merck Sharp & Dohme Corporation, Coordinating Center ASST Papa Giovanni XXIII – Bergamo
    2019Principal Investigator No-profit Study "Post-surgical liquid biopsy- guided treatment of stage III and high-risk stage II colon cancer patients ". Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano
    2019Principal Investigator No-profit Study "A master protocol empowering Precision Research in Colorectal Cancer" Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano
    2019Principal Investigator No-profit Study “Phase II study of avelumab and cetuximab and modified folfoxiri as initial therapy for RAS wild-type unresectable metastatic colorectal cancer”. Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
    2019Principal Investigator No-profit Study “A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting” Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
    2019Principal Investigator No-profit Study “Tracking the evolution of treatment resistance in the VALENTINO clinical trial.” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2019Principal Investigator No-profit Study "Impact of radiomic biomarkers in predicting sensitivity to targeted therapy and molecular status in metastatic colorectal cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2019Principal Investigator No-profit Study “Predictive role of alternative promoters analysis by means of Signomax AP2000 platform in gastrointestinal and bilio-pancreatic cancers treated with immunotherapy” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (Milan), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2019Co-Investigator Profit Study “A phase 2, open-label, single-arm trial of trastuzumab deruxtecan (DS-8201A) in HER2- Positive, unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma subjects who have progressed on or after a trastuzumab-containing regimen”. Promoter DAICHI SANKIO DEVELOPMENT LIMITED, Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
    2019Co-Investigator No-Profit Study “A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer”. Promoter Azienda Unità Sanitaria Locale della Romagna, Coordinating Center Azienda Unità Sanitaria Locale della Romagna
    2019Co-Investigator No-Profit Study “LIBIMET Trial: Redefining the risk of cancer relapse by serum metabolomic and ctDNA in patients with early stage colon cancer” Promoter USL Toscana Centro, Coordinating Center Ospededale Santo Stefano di Prato - Azienda USL Toscana Centro
    2018Principal Investigator No-profit Study "An observational itAlian MulticeNter study on molecular meccanismi of resistine to trAstuzumab in HER-2 positive gastric or gastroesophageal junction (GEJ) cancers: The AMNESIA study" Promoter e Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
    2018Principal Investigator No-profit Study "Randomized phase II study of FOLFOXIRI plus BEVACIZUMAB plus ATEZOLIZUMAB versus FOLFOXIRI plus BEVACIZUMAB as first-line treatment of unresectable metastatic colorectal cancer" Promoter Gruppo GONO - Coordinating Center Azienda Ospedaliera Universitaria Pisana.
    2018Principal Investigator No-profit Study "Randomized phase 2 trial of cetuximab and avelumab or avelumab alone for unresectable, locally advanced or metastatic squamous cell anal carcinoma (SCCAC) progressed after at least one line of systemic treatment" Promoter Gruppo GONO - Coordinating Center Istituto Oncologico Veneto (IOV) - Padova
    2018Principal Investigator No-profit Study "NIVOLUMAB plus IPILIMUMAB and TEMOZOLOMIDE in combination in microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC): the MAYA study" - Promoter Fondazione IRCCS Istituto Nazionale dei Tumori Milano - Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori Milano
    2018Principal Investigator No-profit Study "Phase II study of preoperative chemoradiotherapy plus avelumab in patients with locally advanced rectal cancer" Promoter Gruppo GONO - Coordinating Center Fondazione Policlinico Universitario "A Gemelli" Università Cattolica del Sacro Cuore, Roma
    2018Principal Investigator No-profit Study "Pembrolizumab in mmr-proficient metastatic colorectal cancer pharmacologically primed to trigger dynamic hypermutation status". Promoter IFOM – Istituto FIRC di Oncologia Molecolare, Milano
    2018Co-Investigator No-Profit Study “Prospective and retrospective observational study, multicentric, of evaluation of the FLOT pattern as a perioperative treatment in gastric adenocarcinoma and gastroesophageal Junction (RealFLOT)” Promoter GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC), Coordinating Center Azienda Ospedaliero Universitaria Careggi,Firenze
    2018Co-Investigator Profit Study “A Randomized, Open-label, Phase II Clinical Trial of Relatlimab (anti-LAG-3) and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First- Line Treatment in Patients with Gastric or Gastroesophageal Junction Adenocarcinoma” Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2018Co-Investigator No-Profit Study “A phase II trial of rechallenge with panitumumab driven by ras clonal-mediated dynamic of resistance. the chronos trial.” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO), Coordinating Center Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
    2018Co-Investigator No-Profit Study “Multiplex genotyping of metastatic colorectal cancer patients for precision medicine trials. The FUNNEL Trial” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO), Coordinating Center Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
    2018Co-Investigator no-Profit Study “Adjuvant capecitabine in high risk pseudomyxoma peritonei patients treated with cytoreductive surgery (CRS) and hypertermic intraperitoneal chemotherapy (HIPEC)”. Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2018Co-Investigator no-Profit Study “Phase II multicentre trial of perioperative chemotherapy in operable patients with gastric cancer (Periscope trial)” Promoter Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC), Coordinating Center ASST of Cremona, Cremona
    2017Co-Investigator Profit Study “A Multicenter, Randomized, Open-label, 3-Arm Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA) /Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-mutant Metastatic Colorectal Cancer” Promoter Array BioPharma Inc, Coordinating Center Istituto Europeo di Oncologia (IEO)
    2017Principal Investigator Profit Study “A Phase III, Randomized, Double-blind, Clinical Trial of Pembrolizumab (MK-3475) plus Chemotherapy (XP or FP) versus Placebo plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects with Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)” Promoter Merck Sharp & Dohme S.p.A, Coordinating Center Istituto Oncologico Veneto (IOV) – Padova
    2017Principal Investigator Profit Study “A Randomized Phase 3 Study of Nivolumab plus Ipilimumab or Nivolumab Combined with Fluorouracil plus Cisplatin versus Fluorouracil plus Cisplatin in Subjects with Unresectable Advanced, Recurrent or Metastatic Previously Untreated Esophageal Squamous Cell Carcinoma” Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2017Co-Investigator Profit Study “A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BSC) compared to Placebo plus BSC in Patients with Advanced or Metastatic Gastric Cancer (GC)” Promoter LSK BioPartners, Inc., Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2017Co-Investigator Profit Study “A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Gastric Cancer (FRACTION-Gastric Cancer)” Promoter Bristol-Myers Squibb International Corporation, Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2017Co-Investigator Profit Study “Randomized phase III study of triplet mFOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for unresectable RAS and BRAF wild-type metastatic colorectal cancer patients” Promoter Fondazione Gono Onlus, Coordinating Center Azienda Ospedaliera Universitaria Pisana
    2016Co-Investigator no-Profit Study “The PANDA study: randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wildtype metastatic colorectal cancer elderly patients” Promoter Fondazione Gono Onlus
    2016Co-Investigator Profit Study “A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs” Promoter Bristol- Myers Squibb International Corporation
    2016Co-Investigator Profit Study “A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma” Promoter Gilead Sciences, Inc
    2016Co-Investigator Profit Study “CORRELATE - Safety and Effectiveness of Regorafenib in Routine Clinical Practice Settings” Promoter Bayer Healthcare AG
    2016Co-Investigator Profit Study “A Phase III open-label,multicenter trial of maintenance therapy with avelumab (MSB0010718C) versus continuation of first-line chemotherapy in subjects with unresectable, locally advanced or metastatic, adenocarcinoma of the stomach, or of the gastro-esophageal junction” Promoter Merck KGaA
    2016Co-Investigator Profit Study “Safety and Effectiveness of Ramucirumab in Patients with Advanced Gastric Cancer in the European Union and North America: A Prospective Observational Registry (I4T-MC-JVDD)” Promoter Eli Lilly Italia S.p.A.
    2016Co-Investigator No-Profit Study “Assessment of Ramucirumab plus paclitaxel as switch MANteInance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III Trial” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI), Coordinating Center Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2016Co-Investigator Profit Study “A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma” Promoter F. Hoffmann- La Roche, Ltd
    2016Co-Investigator Profit Study “An open-label early access phase IIIb study of trifluridine / tipiracil (S95005/TAS-102) in patients with a pretreated metastatic colorectal cancer” Promoter Institut de Recherches Internationales Servier
    2015Co-Investigator no-Profit Study “Observational retrospective study on the use of ramucirumab (nominal use) in patients with gastric cancer and gastroesophageal junction, metastatic, progressed after a first-line therapy with platinum derivatives and fluoropyrimidine” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2015Co-Investigator Profit Study “A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)” Promoter Eli Lilly Italia S.p.A.
    2015Co-Investigator Profit Study “Randomized, multi-center, open-label trial of pembrolizumab (MK-3475) versus paclitaxel in subjects with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have progressed after failure of any combination chemotherapy containing a platinum and a fluoropyrimidine agent” Promoter Merck Sharp & Dohme Corporation
    2015Co-Investigator no-Profit Study “Prospective study for the determination of the molecular profile of resistance to "target therapies" in patients with solid tumors - Protocol PROFILING” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
    2015Co-Investigator no-Profit Study “First-line FOLFOX-4 plus panitumumab folowed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type, metastatic colorectal cancer: the VALENTINO study” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2015Co-Investigator no-Profit Study “First-line FOLFOXIRI plus bevacizumab followed by reintroduction of FOLFOXIRI plus bevacizumab at progression versus FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at progression in first- and second-line treatment of unresectable metastatic colorectal cancer . The tribe-2 phase III study” Promoter Fondazione Gono Onlus.
    2015Co-Investigator no-Profit Study “Explorative Evaluation of new potential prognostic factor in patient with gastrointestinal cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2015Co-Investigator no-Profit Study “A phase II, randomized, multicenter study to assess the efficacy of nab-paclitaxel- based doublet as first line therapy in patients with cancer of unknown primary (CUP): the AGNOSTOS trial” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
    2015Co-Investigator no-Profit Study “A multicenter, translational study to investigate the genomic landscape of cancer of unknown primary (CUP): AGNOSTOS PROFILING study” Promoter Fondazione del Piemonte per l'Oncologia - IRCCS Candiolo (TO)
    2014Co-Investigator Profit Study “A multicenter, phase II, single arm, two cohort study evaluating the efficacy, safety, and pharmacokinetics of AMG 337 in subjects with MET amplified gastric/gastroesophageal junction/esophageal adenocarcinoma or other MET amplified solid tumors” Promoter Amgen Dompè S.P.A.
    2014Co-Investigator no-Profit Study “Observational study on perioperative management with COI regimen (Capecitabine plus Oxaliplatin and Irinotecan) in patients with gastric or gastroesophageal locally advanced and technically resectable cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2014Co-Investigator Profit Study “Identification and Characterization of Molecular and Clinical Profiles, and Outcomes in Subjects With MET-Amplified Cancers” Promoter Amgen Dompè S.P.A.
    2014Co-Investigator no-Profit Study “Activation of the druggable pathways in gastric carcinomas and clinical outcomes of metastatic patients treated with trastuzumab” Promoter Università di Urbino - Dipartimento Scienze Biomolecolari
    2014Co-Investigator Profit Study “A multi-centre randomized clinical trial of biomarker-driven maintenance treatment for first-line metastatic colorectal cancer (MODUL)” Promoter Roche S.p.A.
    2014Co-Investigator no-Profit Study “An open-label, randomized, multicenter, phase II trial designed to compare the efficacy of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first-line oxaliplatin-containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancer” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2014Co-Investigator no-Profit Study “Identificazione e caratterizzazione del DNA circolante nel sangue dei pazienti affetti da carcinoma colo-rettale avanzato e valutazione delle sue modificazioni nel corso del trattamento con cetuximab oppure panitumumab, associati o meno a chemioterapia” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2013Co-Investigator no-Profit Study “Retrospective observational study on the use of off-label temozolomide in patients with metastatic colorectal cancer with methylation of the MGMT gene” Promoter Fondazione IRCCS Istituto Nazionale dei Tumori (MI)
    2013Co-Investigator no-Profit Study “A Single-Arm, Open Label Study of Aflibercept as Maintenance Therapy Following Induction with Aflibercept in Combination with XELOX, as First-Line Treatment for Metastatic Colorectal Cancer Patient” Promoter Sanofi-Aventis S.p.A.
    Most relevant Events as Invited Speaker
    October 2026Speaker of “ESMO 2026 HIghlights webinar on GI Cancers”
    04/05/2026New York City: Speaker at Sloan Memorial Hospital: “Biomarker development and ctDNA directed platform studies”
    29/04/2026Valencia: speaker at Inclivia Biomedical Research Institute: “Novel strategies in gastric cancer: moving from additive effect to synergistic combos”
    04-08/12/202512th Guangzhou International Symposium – Relatore nel “Symposium on Oncology” organizzato da Guangzhou Provincial Anticancer Association co-hosted by the Sun Yat-sen University Cancer Center
    17 – 28/10/2025Track Chair at the ESMO 2025 Annual Meeting - Upper Gastrointestinal tumors
    28/10/2025Chair del webinar ESMO 2025: “Congress Highlights on Gastrointestinal Cancers”- as President he managed the whole session taking in the introduction, moderating the panel and facilitating the Q&A session with relevant information on what has been discussed.
    31-01/11/2025Speaker for AMFROM in Tangeri “Non-Metastatic Esogastric Adenocarcinamas: Today’s standards Tomorrow’s Possibilities: Systemic Treatment Optimization Biomarkers as a Guiding Tool”
    17-21/10/2025ESMO Congress 2025, speaker
    01-02/08/2025Relatore per APGS 12th Asia Pacific Gastroenterology Cancer Summit 2025 – Singapore
    06-08/03/2025JSMO Japan a Kobe “Session1: Discussant for Symposium: New Multimodal treatment strategy for GI cancer”; Session 2: Speaker in the Symposium: “New Multimodal treatment strategy for GI cancer: - “NOM for lower GI cancer”
    29/01/2025Darmkrebs im Fokus: KRK25 , speaker via webex for the Session: “Colorectal Cancer in Focus”
    06- 08/12/2024ESMO ASIA Congress 2024, speaker in the Educational Session “Personalising gastrointestinal (GI) oncology: From old to new target inhibition”, giving the lecture: HER2 inhibition: Agnostic approach or disease-specific strategy?”
    02/11/2024EIOC Speaker at APMEA Molecular Tumor Board Session, speaking about GI cancer
    October 2024Speaker of ESMO 2024 “HIghlights webinar on GI Cancers”
    04-05/10/2024European Chapter Congress of the International Gastric Cancer Association 2024 in Siena, as Member of the Scientific Committee for the event entitled: “" The new frontiers of tailored approach and precision medicine for gastric/EGJ cancer"
    26-29/06/2024ESMO 2024 Munich, Talk within the “Multidisciplinary Tumor Board: Gastro Oesophageal Junction Cancer” Speaking about “A Case of MSI GE Junction Cancer”
    30-4/06/2024ASCO 2024 Chicago (USA) during the Oral Abstract Session – Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary, the speech title is: “Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: the ARMANI phase III trial.”
    30-1/12/2023Paris, first meeting of 'SIRIC CURAMUS' dedicated to MSI Cancers. Within the session of Microsatellite Instability and Cancer, presentation in the second session "Understanding genomics": "Inducing MMR deficiency in MSS colorectal cancer”.
    20-24/10/2023ESMO 2023 Madrid, during the Educational Session on “Biomarkers in metastatic colorectal cancer: What has changed in the last few years?” the speech title is “Biomarkers in the near future: What to expect?”. During the Presidential Symposium “LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study”.
    6-7/10/2023EGCC 2023 Ginevra (Svizzera), “Oligomestatic disease" Talk: MSI, PDL-1, HER2, Claudin 18.2 : which influence on treatment strategy; “European Chapter IGCA - Treatment Recommendation" Panel Discussion: Oligomestatic: Indications and Clinical Question”.
    6-11/09/2023ISDE 2023 Toronto (Canada), “Current and Future Status of Immunotherapy in Gastroesophageal Adenocarcinoma Session Details Innovative Approaches and Novel Systemic Therapies – When, Who, and Which?”; “Checkpoint Inhibition for Adenocarcinoma of the Esophagus and EGJ Session Details ISS - Immune-Oncology in Esophageal Cancer”; “Debate – Neoadjuvant Chemotherapy is the optimal approach for locally advanced esophageal adenocarcinoma Session Details Locally Advanced Esophageal Adenocarcinoma”.
    27-1/07/2023ESMO 2023 Barcellona within the Session X: Esophageal and Gastric Cancers: “Locally Advanced MSI-H Upper GI Cancer: What is the Optimal Approach?”
    15-16/06/2023UK Oncology Forum in Bristol (UK), “Making the most from Immunotherapy in gastroesophageal cancers - new targets, combinations and biomarkers”
    18-24/01/2023ASCO 2023 Annual Meeting , San Francisco (USA) Gastrointestinal Cancer Symposium INFINITY: a multi center, single-arm, multi color, phase II trial of tremelimumab and survalumab as neoadjuvant treatment of patients with microsatellite instability-high (MSI) resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC)
    13/04/2022ESMO Deep Dive in Upper GI Cancers. “From biology to clinical experience in dMMR/MSI gastric cancer”
    14/01/2022ESMO Virtual Advanced Course on Innovation and Emerging Knowledge in Colorectal Cancer January 2022.“Treatment strategies in MSS/pMMR mCRC”
    13/01/2022ESMO Virtual Advanced Course on Innovation and Emerging Knowledge in Colorectal Cancer January 2022. “The relevance of stroma in CRC”
    18/09/2021Oral communication ESMO Annual Meeting 2021 “383O - MAYA trial: Temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC)”
    04/09/2020Speaker Immunotherapy in tumors of the gastrointestinal tract - Master of Immuno-oncology dell'Università La Sapienza, Roma.
    31/01/2020Member of the scientific committee and chair II Edition News in Oncology Focus on Gastrointestinal Tumors, Milano. Session “Upper GI cancer treatment”.
    15/11/2019Speaker Seminar "Gastric carcinoma: clinical approach" IRCCS Istituto Candiolo (TO)
    26/10/2019Speaker XXI National Congress AIOM "Less frequent molecular alterations and feasible therapeutic opportunities in tumors of the stomach, biliary tract and pancreas".
    29/09/2019Oral Poster Discussion ASCO 2019 Annual Meeting, Chicago (USA) Gastrointestinal (Colorectal) Cancer Session "A randomized phase II trial of second-line CAPTEM versus FOLFIRI in MGMT methylated, RAS mutated metastatic colorectal cancer (mCRC) patients"
    17/01/2019ASCO Gastrointestinal Cancers Symposium, sessione Cancers of The Esophagus and Stomach, San Francisco (CA). "Poster Walk" MSI-GC-01: Individual patient data (IPD) meta-analysis of microsatellite instability (MSI) and gastric cancer (GC) from four randomized clinical trials (RCTs).
    16/11/2018Speaker XX Congresso Nazionale AIOM. " Mucinous neoplasms of the appendix - treatment"
    07/11/2018Speaker POST ESMO Congress -Woman for Oncology Italy, Padova. "Update colon-retto"
    21/09/2018Speaker National Congress SIC Società Italiana di Cancerologia 2018, Milano. "Evolving landscape of immunotherapy in colorectal cancer"
    22/06/2018Oral communication ESMO World Congress on Gastrointestinal Cancers, Barcelona, Spain. "First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in RAS wild-type metastatic colorectal cancer: the VALENTINO study"
    05/06/2018Oral communication ASCO Annual Meeting 2018, Colorectal Cancer Session . "First-line FOLFOX plus panitumumab followed by 5-FU/LV plus panitumumab or single-agent panitumumab as maintenance therapy in patients with RAS wild-type metastatic colorectal cancer: The VALENTINO study".
    30/06/2017Oral communication ESMO World GI 2017, Barcellona. “RET rearrangements define a new and rare molecular subtype of metastatic colorectal cancer (mCRC)2; abstract O-011. Ann Oncol (2017) 28 (suppl_3).
    16/06/2017Speaker AIOM post ASCO, Bologna. “Colorectal cancer poster review”.
    11/02/2017Speaker AIOM post ASCO GI, Roma. “Colon cancer highlights”.
    29/10/2016Member of the scientific committe and speaker XVIII National Congress AIOM, Roma educational session entitled: Colorectal cancer “Is there a role for biological characterization in adjuvant therapy?"
    29/06/2016Oral communication ESMO World GI 2016. “A new nomogram for estimating 12-weeks survival in patients (pts) with chemorefractory metastatic colorectal cancer (mCRC) (Annals of Oncology, Volume 27, Issue suppl_2, 1 June 2016).
    23/10/2015Speaker and member of the scientific committe XVII National Congress AIOM: " To propose biologic maintenance to all patients after upfront treatment?"
    27/10/2012Speaker XIV Congresso Nazionale AIOM, Roma. “Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy”.
    Original contributions to the literature

    (> 400 articles in international peer-reviewed journals)

    Please find all contributions to the literature to the following link: https://pubmed.ncbi.nlm.nih.gov/?term=Pietrantonio+f.

    Language skills:
    ItalianMothertongue
    EnglishExcellent
    SpanishGood

    In compliance with the Italian legislative Decree no. 196 dated 30/06/2003, I hereby authorize you to use and process my personal details contained in this document. I authorize the treatment of my personal data according to the Art. 13 of the EU regulation 2016/679